NCT02799537 Comparing the Stanford Letter Project Form to Traditional Advance Directives
| NCT ID | NCT02799537 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Stanford University |
| Condition | Advance Directives |
| Study Type | INTERVENTIONAL |
| Enrollment | 1,000 participants |
| Start Date | 2016-02 |
| Primary Completion | 2026-08 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 1,000 participants in total. It began in 2016-02 with a primary completion date of 2026-08.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Our goal is to compare two types of advance directives forms available in English and Spanish to determine which is more easy to use for patients.
Eligibility Criteria
Inclusion Criteria: * Over 18 years of age Exclusion Criteria: * Under 18
Contact & Investigator
VJ Periyakoil, MD
PRINCIPAL INVESTIGATOR
Stanford University
Frequently Asked Questions
Who can join the NCT02799537 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Advance Directives. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02799537 currently recruiting?
Yes, NCT02799537 is actively recruiting participants. Contact the research team at Periyakoil@stanford.edu for enrollment information.
Where is the NCT02799537 trial being conducted?
This trial is being conducted at Stanford, United States.
Who is sponsoring the NCT02799537 clinical trial?
NCT02799537 is sponsored by Stanford University. The principal investigator is VJ Periyakoil, MD at Stanford University. The trial plans to enroll 1,000 participants.